Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2011 Jan 7;10(3):558–565. doi: 10.1158/1535-7163.MCT-10-0994

Figure 1. Waterfall plot of patients with PIK3CA mutations treated with PI3K/AKT/mTOR inhibitors.

Figure 1

Six PRs (5 confirmed) and 6 minor responses less than PR were observed. The overall response rate was 35%. The best response was complete resolution of all measurable disease with persistence of non-measurable disease in a patient with squamous cell cervical carcinoma treated with an mTOR-based regimen. Four patients with colorectal cancer and 1 patient with ovarian cancer had simultaneous KRAS mutations. One patient with ovarian cancer had a simultaneous BRAF mutation.